Britzen-laurent et al. [12] suggested that the loss of GBP1 expression in colorectal cancer suggests that the tumor evades the Th1 immune response dominated by IFN-γ, and GBP1 is involved in the anti-tumor immune response. The gene discussed is IFNG; the disease is neoplasm.